Phase II Study of Rucaparib and Nivolumab in Patients With Leiomyosarcoma
Latest Information Update: 09 Sep 2022
At a glance
- Drugs Nivolumab (Primary) ; Rucaparib (Primary)
- Indications Leiomyosarcoma
- Focus Therapeutic Use
- 06 Sep 2022 Planned End Date changed from 5 Nov 2023 to 5 Nov 2024.
- 06 Sep 2022 Planned primary completion date changed from 5 Nov 2023 to 5 Nov 2024.
- 24 Aug 2022 Planned End Date changed from 5 Nov 2022 to 5 Nov 2023.